Effect of a new somatostatin analogue on pancreatic function in healthy volunteers.
We studied the effect of four graded doses of SMS 201-995, a synthetic octapeptide somatostatin analogue (27, 80, 240, and 720 ng/kg/h) on the basal and secretin-plus-cerulein-stimulated exocrine pancreatic function and pancreatic polypeptide (PP) release in five healthy volunteers. Duodenal fluid secretion and bicarbonate output under basal and stimulated conditions were not significantly affected by any dose of SMS. The basal and stimulated enzyme secretion were decreased in a non-dose-dependent manner by all SMS doses used in the study and showed a 75% inhibition of the secretin-plus-cerulein-stimulated trypsin and amylase output. The cerulein-stimulated PP release was significantly suppressed by all four SMS doses. SMS appears to be a strong inhibitor of pancreatic enzyme secretion, at the same time affecting the PP release.
D000328:Adult; D000681:Amylases / Q000378:metabolism; D001639:Bicarbonates / Q000378:metabolism; D001786:Blood Glucose / Q000032:analysis; D002108:Ceruletide / Q000494:pharmacology; D006801:Humans; D008297:Male; D015282:Octreotide; D010179:Pancreas / Q000378:metabolism*; D010189:Pancreatic Juice / Q000187:drug effects / Q000378:metabolism; D010191:Pancreatic Polypeptide / Q000378:metabolism; D012633:Secretin / Q000494:pharmacology; D013004:Somatostatin / Q000031:analogs & derivatives* / Q000097:blood / Q000494:pharmacology; D014357:Trypsin / Q000378:metabolism
D001639:Bicarbonates; D001786:Blood Glucose; D012633:Secretin; D013004:Somatostatin; D010191:Pancreatic Polypeptide; D002108:Ceruletide; D000681:Amylases; D014357:Trypsin; D015282:Octreotide